• Sales revenue up 4% year-over-year, up 7% on a constant currency basis
• Annual Recurring Revenue (ARR) up 11% year-over-year, up 7% on a constant currency basis
• Underlying EBITDA flat compared to prior corresponding period

IMEXHS Ltd, an innovative provider of medical imaging software and radiology services, has released its 1H FY25 results. The company reported sales revenue of $13.7 million, up 4% year-over-year and up 7% on a constant currency basis. Annual Recurring Revenue (ARR) grew 11% year-over-year to $32.8 million, with the software business ARR up 20% and the radiology services ARR up 6%. Underlying EBITDA was flat compared to the prior corresponding period at $0.3 million. The company's software business saw revenue growth of 11% (excluding a one-off sale in the prior period), driven by increased adoption of the Aquila+ platform and strong customer retention. The radiology services business, including RIMAB, reported a 1% increase in revenue and a return to profitability with an EBITDA of $0.3 million. The company is focused on improving margins and cash flow, with a structured plan to strengthen EBITDA and margins through cost optimization initiatives. The company is also implementing a new market segmentation and pricing strategy to drive profitability and growth. Looking ahead, the company expects to achieve FY25 revenue in the range of $27.5 million to $28.2 million, up 4.0% to 6.6% compared to the prior year, and underlying EBITDA in the range of $1.3 million to $1.6 million, up $0.8 million to $1.1 million compared to the prior year.

The Company expects to achieve the following for FY25: revenue in the range $27.5m to $28.2m - up 4.0 to 6.6% vs prior year, and underlying EBITDA in the range $1.3m to $1.6m - up $0.8m to $1.1m vs prior year.

The company is focused on regional consolidation and growth, pricing optimization, enhancing its value proposition, growing its pipeline, ARR and revenue, improving margins, protecting working capital, and maintaining financial discipline.